IMMUNOMEDICS INC | 2013 | FY | 3


The effect of recording this immaterial error correction affects the presentation of the balance sheets as of June 30, 2013 and 2012, the consolidated statements of comprehensive (loss) income and statements of cash flows for the fiscal years ended June 30, 2013, 2012 and 2011 for certain line items as set forth below (in thousands):

 

     As of June 30, 2013     As of June 30, 2012  
     (As
Reported)
    (As
Revised)
    (As
Reported)
    (As
Revised)
 

Balance Sheets

        

Accounts payable and accrued expenses

   $ 7,165      $ 3,951      $ 5,412      $ 2,982   

Total current liabilities

     9,945        6,731        5,595        3,165   

Accumulated deficit

     (229,254     (226,040     (217,088     (214,658

Total Immunomedics, Inc. stockholders’ equity

     36,966        40,180        32,027        34,457   

Total stockholders’ equity

     36,581        39,795        31,739        34,169   

 

    Fiscal Year Ended
June 30, 2013
    Fiscal Year Ended
June 30, 2012
    Fiscal Year Ended
June 30, 2011
 
    (As
Reported)
    (As
Revised)
    (As
Reported)
    (As
Revised)
    (As
Reported)
    (As
Revised)
 

Statements of Comprehensive (Loss) Income

           

Research and development

  $ 29,165      $ 28,381      $ 24,824      $ 24,256      $ 25,369      $ 24,537   

Total costs and expenses

    36,538        35,754        31,860        31,292        33,732        32,900   

Operating (loss) income

    (31,576     (30,792     874        1,442        (19,023     (18,191

(Loss) income before income tax expense

    (12,226     (11,442     906        1,474        (15,135     (14,303

Net (loss) income

    (12,270     (11,486     696        1,264        (15,244     (14,412

Net (loss) income attributable to Immunomedics, Inc. stockholders

    (12,165     (11,381     810        1,378        (15,070     (14,238

Comprehensive (loss) income

    (12,189     (11,405     382        950        (15,191     (14,359

Comprehensive (loss) income attributable to Immunomedics, Inc. stockholders

    (12,084     (11,300     495        1,063        (15,017     (14,185

Net (loss) income per common share attributable to Immunomedics Inc. to common stockholders – basic

    (0.16     (0.15     0.01        0.02        (0.20     (0.19

Net (loss) income per common share attributable to Immunomedics Inc. common stockholders – fully diluted

    (0.16     (0.15     0.01        0.02        (0.20     (0.19

Weighted average number of common shares outstanding – basic

    78,040        78,040        75,481        75,481        75,313        75,313   

Weighted average number of common shares outstanding – fully diluted

    78,040        78,040        76,174        76,174        75,313        75,313   

Statements of Cash Flows

           

Changes in accounts payable and accrued expenses

    1,751        967        67        (501     1,242        410   

us-gaap:ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock